These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22770610)

  • 61. Development and biological evaluation of a novel aurora A kinase inhibitor.
    Sardon T; Cottin T; Xu J; Giannis A; Vernos I
    Chembiochem; 2009 Feb; 10(3):464-78. PubMed ID: 19199284
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Identification of novel, selective and potent Chk2 inhibitors.
    Larson G; Yan S; Chen H; Rong F; Hong Z; Wu JZ
    Bioorg Med Chem Lett; 2007 Jan; 17(1):172-5. PubMed ID: 17035018
    [TBL] [Abstract][Full Text] [Related]  

  • 63. X-ray Structures and Feasibility Assessment of CLK2 Inhibitors for Phelan-McDermid Syndrome.
    Kallen J; Bergsdorf C; Arnaud B; Bernhard M; Brichet M; Cobos-Correa A; Elhajouji A; Freuler F; Galimberti I; Guibourdenche C; Haenni S; Holzinger S; Hunziker J; Izaac A; Kaufmann M; Leder L; Martus HJ; von Matt P; Polyakov V; Roethlisberger P; Roma G; Stiefl N; Uteng M; Lerchner A
    ChemMedChem; 2018 Sep; 13(18):1997-2007. PubMed ID: 29985556
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors.
    Zeng H; Belanger DB; Curran PJ; Shipps GW; Miao H; Bracken JB; Arshad Siddiqui M; Malkowski M; Wang Y
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5870-5. PubMed ID: 21855335
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A simple set-and-mix assay for screening of protein kinase inhibitors in cell lysates.
    Asami Y; Oishi J; Kitazaki H; Kamimoto J; Kang JH; Niidome T; Mori T; Katayama Y
    Anal Biochem; 2011 Nov; 418(1):44-9. PubMed ID: 21802396
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Structural basis for the inhibitor recognition of human Lyn kinase domain.
    Miyano N; Kinoshita T; Nakai R; Kirii Y; Yokota K; Tada T
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6557-60. PubMed ID: 19857964
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors.
    Schneider G; Geppert T; Hartenfeller M; Reisen F; Klenner A; Reutlinger M; Hähnke V; Hiss JA; Zettl H; Keppner S; Spänkuch B; Schneider P
    Future Med Chem; 2011 Mar; 3(4):415-24. PubMed ID: 21452978
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Design, Synthesis, and Evaluation of Dasatinib-Amino Acid and Dasatinib-Fatty Acid Conjugates as Protein Tyrosine Kinase Inhibitors.
    Tiwari RK; Brown A; Sadeghiani N; Shirazi AN; Bolton J; Tse A; Verkhivker G; Parang K; Sun G
    ChemMedChem; 2017 Jan; 12(1):86-99. PubMed ID: 27875633
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Antitumor studies -- part 2: structure-activity relationship study for flavin analogs including investigations on their in vitro antitumor assay and docking simulation into protein tyrosine kinase.
    Ali HI; Tomita K; Akaho E; Kunishima M; Kawashima Y; Yamagishi T; Ikeya H; Nagamatsu T
    Eur J Med Chem; 2008 Jul; 43(7):1376-89. PubMed ID: 18055068
    [TBL] [Abstract][Full Text] [Related]  

  • 70. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
    Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV
    Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Synthesis and biological evaluation of a triazole-based library of pyrido[2,3-d]pyrimidines as FGFR3 tyrosine kinase inhibitors.
    Le Corre L; Girard AL; Aubertin J; Radvanyi F; Benoist-Lasselin C; Jonquoy A; Mugniery E; Legeai-Mallet L; Busca P; Le Merrer Y
    Org Biomol Chem; 2010 May; 8(9):2164-73. PubMed ID: 20401393
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Designing New Kinase Inhibitor Derivatives as Therapeutics Against Common Complex Diseases: Structural Basis of Microtubule Affinity-Regulating Kinase 4 (MARK4) Inhibition.
    Naz F; Shahbaaz M; Bisetty K; Islam A; Ahmad F; Hassan MI
    OMICS; 2015 Nov; 19(11):700-11. PubMed ID: 26565604
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Design and synthesis of benzoazepin-2-one analogs as allosteric binders targeting the PIF pocket of PDK1.
    Wei L; Gao X; Warne R; Hao X; Bussiere D; Gu XJ; Uno T; Liu Y
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3897-902. PubMed ID: 20627557
    [TBL] [Abstract][Full Text] [Related]  

  • 74. 2,5-Diaminopyrimidines and 3,5-disubstituted azapurines as inhibitors of glycogen synthase kinase-3 (GSK-3).
    Lum C; Kahl J; Kessler L; Kucharski J; Lundström J; Miller S; Nakanishi H; Pei Y; Pryor K; Roberts E; Sebo L; Sullivan R; Urban J; Wang Z
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3578-81. PubMed ID: 18502127
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Synthesis, biological evaluation and docking studies of new pyrrolo[2,3-d] pyrimidine derivatives as Src family-selective tyrosine kinase inhibitors.
    Dincer S; Cetin KT; Onay-Besikci A; Ölgen S
    J Enzyme Inhib Med Chem; 2013 Oct; 28(5):1080-7. PubMed ID: 22957720
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Theoretical analysis of the binding of potential inhibitors to protein kinases MK2 and MK3.
    Araújo PM; da Silva LP; Esteves da Silva JC
    Med Chem; 2015; 11(6):573-9. PubMed ID: 25665652
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Submonomer synthesis of azapeptide ligands of the Insulin Receptor Tyrosine Kinase domain.
    Kurian LA; Silva TA; Sabatino D
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4176-80. PubMed ID: 25127870
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A fluorescence polarization assay for native protein substrates of kinases.
    Kristjánsdóttir K; Rudolph J
    Anal Biochem; 2003 May; 316(1):41-9. PubMed ID: 12694725
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors.
    Cuny GD; Ulyanova NP; Patnaik D; Liu JF; Lin X; Auerbach K; Ray SS; Xian J; Glicksman MA; Stein RL; Higgins JM
    Bioorg Med Chem Lett; 2012 Mar; 22(5):2015-9. PubMed ID: 22335895
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
    Rothweiler U; Eriksson J; Stensen W; Leeson F; Engh RA; Svendsen JS
    Eur J Med Chem; 2015 Apr; 94():140-8. PubMed ID: 25768698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.